{"id":19997,"date":"2022-12-02T20:34:45","date_gmt":"2022-12-02T15:04:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19997"},"modified":"2025-02-12T17:39:53","modified_gmt":"2025-02-12T12:09:53","slug":"pd-1-and-pd-l1-inhibitors-in-cancer-management","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management","title":{"rendered":"PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d1c91b82ee8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d1c91b82ee8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Clinical_Advantage_of_PD-1PD-L1_Blockade_Over_Conventional_Cancer_Therapies\" >Clinical Advantage of PD-1\/PD-L1 Blockade Over Conventional Cancer Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#The_Downsides_of_PD-1_and_PD-L1_Inhibitors_in_Cancer_Treatment\" >The Downsides of PD-1 and PD-L1 Inhibitors in Cancer Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Disease_Recurrence\" >Disease Recurrence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Immune-Related_Events\" >Immune-Related Events<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Nonspecific_Biomarkers\" >Nonspecific Biomarkers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Cost_Effectiveness_of_PD-1_Blockade\" >Cost Effectiveness of PD-1 Blockade<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Resistance_to_Immune_Checkpoint_Blockade\" >Resistance to Immune Checkpoint Blockade<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#PD-1_and_PDL-1_Inhibitors_in_Development\" >PD-1 and PDL-1 Inhibitors in Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Evolving_PD-1_and_PDL-1_Inhibitor_Drugs_Clinical_Trial_Landscape\" >Evolving PD-1 and PDL-1 Inhibitor Drugs Clinical Trial Landscape<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Keytruda_Merck\" >Keytruda: Merck<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Tislelizumab_BeiGene\" >Tislelizumab: BeiGene<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Envafolimab_Tracon_Pharmaceuticals_Inc\" >Envafolimab: Tracon Pharmaceuticals Inc.<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Whats_Trending_in_the_PD-1_and_PDL-1_Inhibitors_Market\" >What\u2019s Trending in the PD-1 and PDL-1 Inhibitors Market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\/#Looking_Into_the_Future_of_the_PD-1_and_PDL-1_Inhibitors_Market\" >Looking Into the Future of the PD-1 and PDL-1 Inhibitors Market<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via its interaction with the PDL1 ligand. Activation of PD1\/PDL1 signaling has been suggested as a mechanism for tumors to invade an antigen-specific T-cell immunologic response in preclinical studies.<\/p>\n\n\n\n<p>Several immunomodulatory agents that target immune checkpoints are available. The FDA has approved PDL1 to treat a variety of cancers, including lung cancer, malignant melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, and Hodgkin lymphoma.<\/p>\n\n\n\n<p>PDL-1 and PDL-2 (B7 family) are binding ligands for PD-1, a member of the CD28 family, and are expressed on T-cells, B-cells, macrophages, and dendritic cells. T-cell activity is inhibited, T-cell tolerance is induced, proliferation is suppressed, and the immune response to T-cells is reduced when either ligand binds.<\/p>\n\n\n\n<p>The combination of PD-1 and PDL-1 acts as an immune \u201cbrake,\u201d inhibiting T-cell activity and preventing immune cells from killing cancer cells. There are several <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/pd1-pdl1-inhibitors-whitepaper\">FDA-approved PD-1\/PD-L1 inhibitor drugs<\/a> for the treatment of various types of tumors. <strong>Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, and Avelumab<\/strong> are some of the most commonly used PD-1\/PDl-1 inhibitors in clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-advantage-of-pd-1-pd-l1-blockade-over-conventional-cancer-therapies\"><span class=\"ez-toc-section\" id=\"Clinical_Advantage_of_PD-1PD-L1_Blockade_Over_Conventional_Cancer_Therapies\"><\/span><strong>Clinical Advantage of PD-1\/PD-L1 Blockade Over Conventional Cancer Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Compared to cancer therapies, the advantage of immunotherapy is the functionality of the immune system; the specificity of the set immunotherapy to a specific tumor. PD-1 inhibitor monotherapies are known to be associated with higher survival rates than other immune checkpoint inhibitor monotherapies, such as ipilimumab (anti-CTLA-4 monoclonal antibody) and BRAF\/MEK inhibitors. Furthermore, the PD-1 inhibitor pembrolizumab is now regarded as a new frontline therapy and standard of care.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"558\" height=\"365\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155204\/PD-1PD-L1-Combined-Treatment-Regimen.png\" alt=\"PD-1\/PDL-1 Inhibitor Combined Treatment Regimen\" class=\"wp-image-20011\" style=\"width:558px;height:365px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155204\/PD-1PD-L1-Combined-Treatment-Regimen.png 558w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155204\/PD-1PD-L1-Combined-Treatment-Regimen-300x196.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155204\/PD-1PD-L1-Combined-Treatment-Regimen-150x98.png 150w\" sizes=\"(max-width: 558px) 100vw, 558px\" \/><figcaption class=\"wp-element-caption\"><strong> PD-1\/PD-L1 Inhibitors: Key Insights Into the Combined Treatment Strategies<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Various studies have shown that the toxicity associated with PD-1 blocking agents is less than that associated with other immunotherapies. Because it is non-invasive and natural, PD-1\/L1 blockade is safer than other monotherapy approaches, such as chemotherapy, surgery, and radiation. Moreover, as <a href=\"https:\/\/www.delveinsight.com\/blog\/checkpoint-inhibitors-for-refractory-cancer-treatment\">checkpoint immunotherapy<\/a> is highly specific to target cells, it has fewer dangerous side effects. A PD-1 blockade is effective against a wide range of cancers and has a longer duration of action because it activates an anti-tumor immune system that can target mutated proteins.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Downsides_of_PD-1_and_PD-L1_Inhibitors_in_Cancer_Treatment\"><\/span><strong>The Downsides of PD-1 and PD-L1 Inhibitors in Cancer Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite their significant potential, there are drawbacks of PD-1\/PDL-1 inhibitors in cancer treatment. These drawbacks highlight the need for more research into the mechanisms underlying therapeutic effects and the development of novel biomarkers to predict treatment failure and monitor potential adverse events. The major <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-L1-inhibitors-market\" class=\"ek-link\">drawbacks of PD-1\/PDL-1 inhibitors in cancer treatment<\/a> include<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"643\" height=\"172\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02154852\/Drawbacks-of-PD-1-PDL-1-Inhibitors-in-Cancer-Management-1.png\" alt=\"Drawbacks of PD-1\/PD-L1 Inhibitors in Cancer Management\" class=\"wp-image-20008\" style=\"width:643px;height:172px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02154852\/Drawbacks-of-PD-1-PDL-1-Inhibitors-in-Cancer-Management-1.png 643w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02154852\/Drawbacks-of-PD-1-PDL-1-Inhibitors-in-Cancer-Management-1-300x80.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02154852\/Drawbacks-of-PD-1-PDL-1-Inhibitors-in-Cancer-Management-1-150x40.png 150w\" sizes=\"(max-width: 643px) 100vw, 643px\" \/><figcaption class=\"wp-element-caption\"><strong>PD-1\/PD-L1 Inhibitors in Cancer &#8211; Major Limitations and Downsides<\/strong><\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Disease_Recurrence\"><\/span><strong>Disease Recurrence<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>PD-1 inhibitors are associated with higher rates of disease occurrence when compared to CTLA-4 inhibitors. <a href=\"https:\/\/www.delveinsight.com\/blog\/checkpoint-inhibitors-for-refractory-cancer-treatment\">Checkpoint inhibitor-treated patients<\/a> eventually develop progressive disease. When treated with checkpoint inhibitors, <strong>18% <\/strong>of them can develop oligoprogression. On the other hand, patients receiving local therapy frequently experience long-term progression-free survival. As a result, it is critical to identify disease recurrence predictors that are significant in identifying patients who may not benefit from immune checkpoint inhibitors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Immune-Related_Events\"><\/span><strong>Immune-Related Events<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The most notable disadvantage of this oncotherapy is the occurrence of immune-related side effects. With repeated doses of anti-PD-1\/PDL-1 antibodies, more fatal hypersensitive reactions occur. They have the potential to cause a variety of immune-related side effects in organs such as the pancreas, skin, liver, renal system, and gastrointestinal tract.<\/p>\n\n\n\n<p>Furthermore, pneumonitis associated with PD-1 blockade is a significant adverse event seen primarily in <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">patients with non-small cell lung cancer<\/a>. Meningoradiculitis, polyradiculitis, cardiac arrhythmia, asystole, and paresis have also been reported as side effects. Pembrolizumab has been linked to a number of side effects in patients, including heart failure and myocarditis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nonspecific_Biomarkers\"><\/span><strong>Nonspecific Biomarkers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Although PDL-1 is a validated and important predictive biomarker, it is insufficient and specific to determine which patients should be given anti-PD-1\/PDL-1 antibodies. It has been proposed that a tumor expressing the highest level of PDL-1\/2 is the most responsive to therapy; however, this has yet to be approved. Similarly, regardless of tumor type, MSI and dMMR have been proposed as prognostic biomarkers of response to PD-1\/PDL-1 inhibitors. These phenotypes are also insufficient to fully predict drug response because they are frequently observed in many cancers and thus lack specificity.<\/p>\n\n\n\n<p>According to the current research, tumors with high PDL-1 expression and TMI, MSI, or dMMR have a higher response rate to PD-1 blockade. As a result, PDL-1 predictive value alone as a biomarker is currently insufficient to understand the depth of the tumor\u2019s landscape. It suggests further research to identify other markers, such as TIL, TMB, IFN- genetic and epigenetic variation, circulating biomarkers, and gut microbiota.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cost_Effectiveness_of_PD-1_Blockade\"><\/span><strong>Cost Effectiveness of PD-1 Blockade<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>PD-1 blockade monotherapies are generally more expensive than other immunotherapy regimens and conventional cancer therapies. The main risk factor for developing cancer is advanced age, which is primarily due to a decline in immune cell generation. As a result, it is assumed that there are a large number of elderly cancer patients.<\/p>\n\n\n\n<p>This emphasizes the burden placed on older people, whose income is lower than that of the rest of the population. This emphasizes the burden placed on older people, whose income is lower than the rest of the population. It may provide knowledge for the proper use of checkpoint blockade.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Resistance_to_Immune_Checkpoint_Blockade\"><\/span><strong>Resistance to Immune Checkpoint Blockade<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Although PD-1 signaling blockade has been shown to significantly improve anti-tumor response, produce a long-lasting clinical response, and prolong survival in some cases, approximately <strong>30%-60% <\/strong>of patients do not respond to PD-1\/PD-L1 blockade. Several immune checkpoint blockade resistance mechanisms have been investigated, including defects in class I antigen presentation, the Wnt\/-catenin pathway, and interferon signaling defects. The inhibition of PD-1\/PDL-1 can increase anti-tumor T-cell reactivity and promote immune control over cancerous cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PD-1_and_PDL-1_Inhibitors_in_Development\"><\/span><strong>PD-1 and PDL-1 Inhibitors in Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Over<strong> 180+<\/strong> PD-1 and PD-L1 inhibitors companies, including <strong>Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH &amp; Co. KG, Arbutus Biopharma, ABL bio, Macrogenics, AnaptysBio, <\/strong>and others<strong> <\/strong>are evaluating <strong>200+<\/strong> PD-1 and PD-L1 inhibitors pipeline therapies in various stages of development. <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-inhibitor-pipeline-insight\">PD-1 inhibitor drugs<\/a>, such as <strong>Nivolumab, Pembrolizumab, and Cemiplimab<\/strong>, and PDL-1 inhibitor drugs, such as <strong>Atezolizumab, Avelumab, and Durvalumab<\/strong>, are currently in clinical trials.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"856\" height=\"220\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155317\/PD-1-PDL-1-Emerging-Pipeline-Therapies-Major-Molecule.png\" alt=\"PD-1\/PD-L1 Inhibitors Emerging Pipeline Therapies Molecule\" class=\"wp-image-20012\" style=\"width:856px;height:220px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155317\/PD-1-PDL-1-Emerging-Pipeline-Therapies-Major-Molecule.png 856w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155317\/PD-1-PDL-1-Emerging-Pipeline-Therapies-Major-Molecule-300x77.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155317\/PD-1-PDL-1-Emerging-Pipeline-Therapies-Major-Molecule-150x39.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155317\/PD-1-PDL-1-Emerging-Pipeline-Therapies-Major-Molecule-768x197.png 768w\" sizes=\"(max-width: 856px) 100vw, 856px\" \/><figcaption class=\"wp-element-caption\"><strong> PD-1\/PD-L1 Inhibitors: Therapeutic Assessment By Molecule Type<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Six more immune checkpoint inhibitors have been approved for cancer therapy since the approval in 2011. Moreover, the number of clinical trials involving PD-1\/PD-L1-targeting agents is rapidly increasing, with the majority of these trials involving at least one US FDA-approved agent. The majority of the PD-1\/PDL-1 agents in the trial are monoclonal antibodies, vaccines, small molecules, fusion proteins, peptides, proteins, <a href=\"https:\/\/www.delveinsight.com\/blog\/emerging-rna-interference-drugs\">RNAi<\/a>, and cell therapy, indicating a robust pipeline. The proportion of PD-1\/PD-L1-blocking drug trials that are monotherapy is steadily decreasing, while the number of combination studies is increasing. Several trials are underway to evaluate PD-1\/PD-L1 immunotherapies in combination with other immunotherapies, targeted therapy, chemotherapies, and radiation therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Evolving_PD-1_and_PDL-1_Inhibitor_Drugs_Clinical_Trial_Landscape\"><\/span><strong>Evolving PD-1 and PDL-1 Inhibitor Drugs Clinical Trial Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Some of the drugs in the late stages of development include <strong>Envafolimab, Keytruda, Durvalumab, CA 170, Tislelizumab, Geptanolimab<\/strong>, and others. The anticipated launch of these drugs will significantly increase <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-and-pd-l1-inhibitors-competitive-landscape\">PD-1 and PD-L1 inhibitors market<\/a> revenue. The detailed assessment of some PD-1 and PD-L1 inhibitor drugs are<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"904\" height=\"348\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155946\/PD-1PD-L1-Inhibitors-Pipeline-Assessment.png\" alt=\"PD-1 and PDL-1 Inhibitor Pipeline\" class=\"wp-image-20016\" style=\"width:904px;height:348px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155946\/PD-1PD-L1-Inhibitors-Pipeline-Assessment.png 904w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155946\/PD-1PD-L1-Inhibitors-Pipeline-Assessment-300x115.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155946\/PD-1PD-L1-Inhibitors-Pipeline-Assessment-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02155946\/PD-1PD-L1-Inhibitors-Pipeline-Assessment-768x296.png 768w\" sizes=\"(max-width: 904px) 100vw, 904px\" \/><figcaption class=\"wp-element-caption\"> <strong>Promising  PD-1 and PDL-1 Inhibitor Drugs in Development<\/strong> <\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Keytruda_Merck\"><\/span><strong>Keytruda: Merck<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Merck\u2019s Keytruda <\/strong>is a humanized monoclonal antibody that binds to the programmed cell death &#8211; 1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response. Keytruda has been approved for advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, classical Hodgkin lymphoma, microsatellite-instability-high cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma, and advanced urothelial bladder cancer.&nbsp;<\/p>\n\n\n\n<p>In September 2022, <strong>Merck <\/strong>announced that <strong>KEYTRUDA<\/strong>, Merck\u2019s anti-PD-1 therapy, received four new approvals from Japan\u2019s Ministry of Health, Labor and Welfare (MHLW): <strong>KEYTRUDA <\/strong>in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer at high risk of recurrence, based on data from the KEYNOTE-522 trial; <strong>KEYTRUDA <\/strong>as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions, based on data from the <strong>KEYNOTE-564 trial<\/strong>; <strong>KEYTRUDA <\/strong>in combination with chemotherapy, with or without bevacizumab, for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\">treatment of patients with advanced or recurrent cervical cancer<\/a> with no prior chemotherapy who are not amenable to curative treatment, based on data from the <strong>KEYNOTE-826 trial<\/strong>; <strong>KEYTRUDA <\/strong>as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection, based on data from the <strong>KEYNOTE-716 trial. <\/strong>Currently, it is in the pre-registration stage for Adenocarcinoma.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tislelizumab_BeiGene\"><\/span><strong>Tislelizumab: BeiGene<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Tislelizumab (BGB-A317)<\/strong> is a humanized IgG4 anti-PD-1 monoclonal antibody designed to reduce binding to FcR on macrophages. Binding to FcR on macrophages has been shown in pre-clinical studies to reduce the anti-tumor activity of PD-1 antibodies by activating antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate developed from BeiGene&#8217;s immuno-oncology biologic program, and it has the potential to be an important component of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies to treat a wide range of solid tumors and hematologic cancers.<\/p>\n\n\n\n<p>Tislelizumab is being studied in pivotal Phase III and Phase II clinical trials for solid tumors and hematologic cancers, including a pivotal Phase II trial for <a href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-hl-market\">relapsed\/refractory classical Hodgkin&#8217;s lymphoma (R\/R cHL) treatment<\/a>. It is also being studied in several global Phase III trials, including non-small cell lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma, as well as two global Phase II trials in patients with previously treated hepatocellular carcinoma or R\/R mature T- and NK-cell lymphomas, and an additional pivotal Phase II trial in China in urothelial cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Envafolimab_Tracon_Pharmaceuticals_Inc\"><\/span><strong>Envafolimab: Tracon Pharmaceuticals Inc.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Envafolimab<\/strong>, developed by <strong>Tracon Pharmaceuticals Inc.<\/strong>, is a novel, single-domain PD-L1 antibody that is given subcutaneously without using an adjuvant. Envafolimab is currently being dosed in the <strong>ENVASARC <\/strong>pivotal Phase II trial in the United States, which is being sponsored by <strong>TRACON <\/strong>and has been approved for priority review by the Chinese National Medical Products Administration for the treatment of MSI-H cancer patients. Envafolimab is also being studied in a Phase III registration trial in biliary tract cancer in combination with gemcitabine and oxaliplatin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Whats_Trending_in_the_PD-1_and_PDL-1_Inhibitors_Market\"><\/span><strong>What\u2019s Trending in the PD-1 and PDL-1 Inhibitors Market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>October 2022,<\/strong> <strong>ChemoCentryx, Inc.<\/strong> announced two upcoming poster presentations for CCX559, the Company\u2019s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held November 8-12, 2022, in Boston, MA.<\/li>\n\n\n\n<li>In <strong>October 2022, Compugen Ltd.,<\/strong> a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that it would present new clinical data from its COM701\/nivolumab with or without BMS-986207 combination studies in patients with platinum-resistant ovarian cancer as well as data from the COM701 with or without nivolumab study in <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-market\">patients with metastatic NSCLC<\/a>, as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.<\/li>\n\n\n\n<li>In <strong>October 2022, Imjudo (tremelimumab)<\/strong> from <strong>AstraZeneca <\/strong>was approved in the United States in combination with Imfinzi (durvalumab) for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatocellular-carcinoma-market\">treatment of adult patients with unresectable hepatocellular carcinoma (HCC)<\/a>, the most common type of liver cancer.<\/li>\n\n\n\n<li>In <strong>October 2022, GSK<\/strong> announced positive top-line results from the PERLA phase II trial, which met its primary endpoint of objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined by blinded independent central review.<\/li>\n\n\n\n<li>In <strong>September 2022, Merck<\/strong> announced that KEYTRUDA, Merck\u2019s anti-PD-1 therapy, received four new approvals from Japan\u2019s Ministry of Health, Labor, and Welfare (MHLW).<\/li>\n\n\n\n<li>In<strong> July 2022, TRACON Pharmaceuticals,&nbsp; Inc.<\/strong> announced the enrollment of the 36th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed. The interim analysis is expected to occur in the fourth quarter of this year.<\/li>\n\n\n\n<li>In<strong> January 2022, Merck <\/strong>announced that the European Commission had approved KEYTRUDA as monotherapy for the adjuvant <a href=\"https:\/\/www.delveinsight.com\/report-store\/renal-cell-carcinoma-market\">treatment of adults with renal cell carcinoma (RCC)<\/a> at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Looking_Into_the_Future_of_the_PD-1_and_PDL-1_Inhibitors_Market\"><\/span><strong>Looking Into the Future of the PD-1 and PDL-1 Inhibitors Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The development of PD-1\/PD-L1 inhibitors has become an exciting and expanding field of study. The PD-1\/PDL-1 pathway is well-known for promoting cancer development and progression by negatively regulating T-cell-mediated responses. The use of PD-1\/PDL-1 blockade therapy in solid and hematologic cancers has shown promising anti-tumor effects. However, it has been demonstrated that <strong>30%-60%<\/strong> of patients develop resistance to <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-and-pd-l1-inhibitors-competitive-landscape\">PD-1\/PDL-1 therapy<\/a>. As a result, a thorough understanding of resistance mechanisms and the factors required to overcome them is critical for improving clinical outcomes.<\/p>\n\n\n\n<p>Currently, six PD-1 or PDL-1 directed mAbs in clinical use, with anti-tumor efficacy in over twenty cancer types. However, they have drawbacks, primarily due to the poor pharmacokinetic properties of mAbs. Furthermore, there are challenges in targeting the flat binding site of the protein-protein interaction between PD-1\/PDL-1. Still, small molecule PD-1\/PDL-1 inhibitors have shown much promise in this research area. When considering the broad range of potential combined therapies, a better understanding of the cellular and molecular mechanisms of resistance and synergies will aid in rational design. When taken as a whole, the future landscape of combination strategies is very promising.<\/p>\n\n\n\n<p>Despite the success in <a href=\"https:\/\/www.delveinsight.com\/blog\/oncology\">multiple types of cancer<\/a>, it is estimated that the majority of patients will respond positively to PD-1\/PDL-1 blockade, and primary resistance eventually leads to progression in patients with clinical responses. As a result, the limitation in clinical response reduces efficacy and limits its future application. There is currently a need to improve the efficacy of PD-1\/PDL-1 blockade by discovering novel, predictive, prognostic, and diagnostic biomarkers to make immunotherapy a more targeted treatment with better clinical outcomes and fewer side effects.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-and-pd-l1-inhibitors-competitive-landscape\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-1024x256.png\" alt=\"PD-1 and PD-L1 Inhibitors Market Scenario\" class=\"wp-image-20003\" style=\"width:1024px;height:256px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130706\/PD-1-and-PD-L1-Inhibitors-Market-Scenario.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via its interaction with the PDL1 ligand. Activation of PD1\/PDL1 [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":20000,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[116,140,927,345,454,455,456,3069,457],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-19997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biomarkers-of-pd-1-and-pd-l1-inhibitors","tag-cancer-therapy","tag-cancer-treatment","tag-keytruda","tag-pd-1-and-pd-l-1-inhibitors","tag-pd-1-and-pd-l-1-inhibitors-competitive-landscape","tag-pd-1-and-pd-l1-inhibitors","tag-pd-1-inhibitor","tag-pd-1pdl-1","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Potential of PD-1 and PD-L1 Inhibitors in Cancer Management<\/title>\n<meta name=\"description\" content=\"Over 180+ companies are evaluating their lead PD-1 and PD-L1 inhibitors in different clinical development to improve the treatment landscape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Potential of PD-1 and PD-L1 Inhibitors in Cancer Management\" \/>\n<meta property=\"og:description\" content=\"Over 180+ companies are evaluating their lead PD-1 and PD-L1 inhibitors in different clinical development to improve the treatment landscape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-02T15:04:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T12:09:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130440\/pd-and-pd-l1-inhibitors-in-cancer-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Potential of PD-1 and PD-L1 Inhibitors in Cancer Management","description":"Over 180+ companies are evaluating their lead PD-1 and PD-L1 inhibitors in different clinical development to improve the treatment landscape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management","og_locale":"en_US","og_type":"article","og_title":"Potential of PD-1 and PD-L1 Inhibitors in Cancer Management","og_description":"Over 180+ companies are evaluating their lead PD-1 and PD-L1 inhibitors in different clinical development to improve the treatment landscape.","og_url":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-12-02T15:04:45+00:00","article_modified_time":"2025-02-12T12:09:53+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130440\/pd-and-pd-l1-inhibitors-in-cancer-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management","url":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management","name":"Potential of PD-1 and PD-L1 Inhibitors in Cancer Management","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130440\/pd-and-pd-l1-inhibitors-in-cancer-treatment.png","datePublished":"2022-12-02T15:04:45+00:00","dateModified":"2025-02-12T12:09:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Over 180+ companies are evaluating their lead PD-1 and PD-L1 inhibitors in different clinical development to improve the treatment landscape.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-in-cancer-management#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130440\/pd-and-pd-l1-inhibitors-in-cancer-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130440\/pd-and-pd-l1-inhibitors-in-cancer-treatment.png","width":772,"height":482,"caption":"pd-and-pd-l1-inhibitors-in-cancer-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/02130440\/pd-and-pd-l1-inhibitors-in-cancer-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">biomarkers of PD-1 and PD-L1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cancer therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">biomarkers of PD-1 and PD-L1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">cancer therapy<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 2, 2022","modified":"Updated on Feb 12, 2025"},"absolute_dates_time":{"created":"Posted on Dec 2, 2022 8:34 pm","modified":"Updated on Feb 12, 2025 5:39 pm"},"featured_img_caption":"pd-and-pd-l1-inhibitors-in-cancer-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19997"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19997\/revisions"}],"predecessor-version":[{"id":31050,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19997\/revisions\/31050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20000"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19997"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19997"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}